Benchmark Capital upgrades Myriad Genetics (Nasdaq: MYGN) from Hold to Buy. Price target raised to $88.

Benchmark ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE